for me to know for others to guess
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MZEI Want to know what R & D expenses brings to the table...your potential Health & Safety
Sky
MRSA Breakthrough Announced for the AsepticSure(TM) Hospital Sterilization System
Tuesday 11/10/2009 8:35 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
MZEI 0.275 0.00%
As of 3:59 PM ET 11/11/09
Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that following several months of research, AsepticSure(TM) can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, "Our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure(TM), since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION. This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure(TM) will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials."
Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company's Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Current trials are now being expanded to include a hospital mock-up to be followed by hospital beta testing. Initial sales are targeted to commence early in 2010.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations: 415-868-0300 / web site: www.medizoneint.com
E-mail: operations @ medizoneint.com
SOURCE Medizone International, Inc.
http://www.medizoneint.com
Form 10-Q for MEDIZONE INTERNATIONAL INC
--------------------------------------------------------------------------------
12-Nov-2009
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
General
Medizone International, Inc. ("Medizone" or the "Company"), prior to 2008 had been dedicated to (i) seeking regulatory approval of a precise mixture of ozone and oxygen, and its process of inactivating lipid-enveloped viruses for the intended purpose of decontaminating blood and blood products and assisting in the treatment of certain diseases; (ii) developing or acquiring the related technology and equipment for the medical application of its products, including a drug production and delivery system; and (iii) applying its novel technology to the problem of nosocomial infections world-wide. Beginning in 2008, management re-positioned the Company to pursue an initiative in the field of hospital sterilization.
Corporate Redirection
Early in 2008, our management and board of directors began to consider other applications of our core technologies and new technologies with lower development costs with the objective of moving us to revenue production in the shortest period of time.
Since that time, management has worked to position us to pursue an initiative in the field of hospital sterilization. This change in focus is based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community. Management believes that there is an opportunity to build on our experience with ozone technologies and its bio-oxidative qualities in pursuing this initiative. We have shifted our near term efforts towards one of its founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing biological fluids (blood, serum, and plasma and its fractionates) as well as biologically contaminated equipment and spaces.
We believe that our unique ozone generating technologies could play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as "the silent epidemic" (American Academy of Orthopedic Surgeons, May 2008, copy on file with the Company ("AAOS Study")), a reference to MRSA (methicillin-resistant staphylococcus aureus) infection. This is a strain of Staphylococcus aureus bacteria ("staph") that is resistant to the broad-spectrum antibiotics commonly used to treat it. MRSA can be fatal. According to the AAOS Study, "the number of hospital admissions for MRSA has exploded in the past decade. By 2005, admissions were triple the number in 2000 and 10-fold higher than in 1995. In 2005, in the United States alone, 368,600 hospital admissions for MRSA - including 94,000 invasive infections - resulted in 18,650 deaths. The number of MRSA fatalities in 2005 surpassed the number of fatalities from hurricane Katrina and AIDS combined and is substantially higher than fatalities at the peak of the U. S. polio epidemic." Indeed, biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control or "CDC" (CDC Report, 17 Oct, 2007, copy on file with the Company), as one of the greatest threats to public health and safety in the industrial world. This concern was reflected in an article recently published in the journal Science (18 July 2008, Vol 321, pp 356-361, copy on file with the Company) which estimated that hospital-based infections in 2006 accounted for almost 100,000 deaths in the US alone.
In response to this situation, we are currently developing a highly portable, low-cost, ozone-based technology ("AsepticSure�") specifically for the purpose of decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units. Since this technology is not considered a medical treatment or a diagnostic, its development pathway is not subject to a stringent and expensive regulatory review process. The development pathway will be based on independent peer-reviewed science and engineering excellence.
In 2008, we entered into a five-year agreement with BiOzone Corporation ("BiOzone"). Under the agreement, BiOzone has been developing, along with us, equipment for specialized laboratory trials, a prototype AsepticSure� system for hospital beta-testing and ozone destruct technology. The agreement also covers initial product manufacturing by BiOzone exclusively for Medizone. Under this agreement, we retain the right to outsource additional manufacturing capacity.
During May 2009, we commenced the first of a series of trials designed to confirm that our AsepticSure� Hospital Sterilization System can rapidly eliminate hospital-based bacterial pathogens known to be responsible for the growing number of deaths and serious infections currently plaguing the healthcare system worldwide. We have engaged an internationally recognized expert in medical microbiology and hospital infections to lead the trials. A second series of laboratory trials were commenced in early June 2009, after the first series produced results that management believes to have demonstrated significant bactericidal effects against C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections. This second series
of laboratory trials resulted in what management believes to be levels of bactericidal action necessary to achieve our commercial objectives.
A third series of laboratory trials were commenced during October 2009 in order to establish the precise protocols necessary in order to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. Most recently, our research has shown that the technology can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. We now believe that this development will significantly expand the utility for the AsepticSure� technology.
Simultaneously with this recent testing, a development prototype is being finalized in order to conduct a full room scale hospital mock-up. If the hospital mock-up is successful, we will proceed to hospital beta testing of the production prototype in preparation for marketing. Commercialization of the system, with first product deliveries, is expected during the first half of 2010.
In addition to the hospital sterilization initiative, we have developed an ozone-destruct unit which is used following sterilization of the treated infrastructure to reverse the ozone gas (O3) in the space, and turn it back into O2 in a short period of time. We have targeted initially the treatment of a typically sized surgical suite including sterilization followed by ozone destruct to habitable standards in two hours or less. This short turn-around period is considered of great importance relative to commercialization of the technology.
In parallel research recently conducted at BiOzone, our engineering development partner, it was confirmed that the AsepticSure� hospital sterilization system can complete the entire decontamination process with minimal disturbance to normal hospital flow patterns. We believe that from a commercial viewpoint, the higher the "kill rate" in the shortest turn-around time, the more favorably physicians and hospital administrators will view the system.
An application for registration of a trademark has been filed for the system with the United States Patent and Trademark Office for the mark AsepticSure�. The mark is used to describe a portable decontamination and sterilization system for hospitals, government buildings, schools and other functionally critical environments that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents such as C difficile, E coli, Pseudomonas aeruginous, MRSA and VRE (Vanocomycin-resistant Enterococci - another drug-resistant bacteria).
In July 2009, we filed a patent application for the AsepticSure� technology in order to establish protection of its commercial rights to this technology internationally. The patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings. A second patent filing is expected in the near future to cover the recent testing results as explained above. Also effective July 1, 2009, we entered into a lease agreement and established our own certified laboratory located at Innovation Park, Queen's University in Kingston, Ontario, Canada, which will provide us with a primary research and development platform as we proceed towards commercialization of the AsepticSure � product.
We believe our research and development time frame as well as intellectual property development remain on track. Once the trial program for the AsepticSure� hospital sterilization system is concluded, we expect to out-source the manufacturing of the product and ultimately, partner with a large corporation for the sales and marketing of the final product.
Canadian Foundation for Global Health (CFGH) - Consolidated Variable Interest Entity
We assisted in the formation of the Canadian Foundation for Global Health ("CFGH"), a not-for-profit foundation based in Ottawa, Canada. We helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with Medizone for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for us to use a tiered pricing structure for services and products in emerging economies and extend the reach of our technology to as many in need as possible.
The CFGH is specifically not authorized to contract for research or other services on our behalf without prior approval. All intellectual property, including but not limited to, scientific results, patents and trademarks that are derived from work done on our behalf or at our request, by CFGH or parties contracted by CFGH with our prior approval, are the sole and exclusive property of Medizone.
The CFGH is registered as a not-for-profit corporation under Canadian Federal Charter. CFGH maintains offices at 170 Lauier Avenue West in Ottawa, Canada.
Dr. Michael E. Shannon M.A., M.Sc., M.D. is President of the CFGH and maintains offices at the CFGH. Dr. Shannon is also a member of our board of directors and is our Director of Medical Affairs. Mr. Brad Goble, President of TDVGlobal, Inc., is also a board member of the CFGH and serves
as the Secretary-Treasurer for the organization. According to its website, TDVGlobal, Inc. "is a strategic management consulting company" focusing on the public sector. It is based in Ottawa, Ontario, Canada. Other members of the CFGH board are Edwin G. Marshall (our CEO and Chairman), Daniel D. Hoyt, a director of the Company, and Jill C. Marshall, NMD, Mr. Marshall's wife and a former corporate officer of the Company.
In January 2003, the Financial Accounting Standards Board issued a new accounting standard which requires a variable interest entity ("VIE") to be consolidated by a company if that company absorbs a majority of the VIE's expected losses and/or receives a majority of the entity's expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it. We have determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial condition and operations of CFGH are being consolidated with Medizone as of and for the nine months ended September 30, 2009.
Results of Operations
We were incorporated in January 1986. We are a development stage company primarily engaged in research into the medical uses of ozone. We have not generated, and cannot predict when or if we will generate, revenues or sufficient cash flow to fund continuing or planned operations. If we fail to obtain additional funding, we will be forced to suspend or permanently cease operations, and may need to seek protection under United States bankruptcy laws.
Three Months Ended September 30, 2009 and 2008
There were no sales during the quarters ended September 30, 2009 or 2008. For the three months ended September 30, 2009, we had a net loss of $472,994, compared with a net loss for the three months ended September 30, 2008 of $192,913. Our primary expense is payroll and other office costs, research, development, and consulting fees, together with interest expense and additional expense recorded as a result of options granted, and the extension of certain stock purchase warrants outstanding.
For the three months ended September 30, 2008, we had no research and development expenses. For the three months ended September 30, 2009, however, we incurred $165,237 in research and development costs, as a result of prototype development costs, consulting, and other research activities. Since inception, we have spent a total of $3,035,004 for research and development related to its ozone technology and related apparatus. Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development.
General and administrative expenses in the quarter ended September 30, 2009, were $301,149 compared to $186,870 during the same period in 2008. The increase in the current year as compared to the prior year was related to additional payroll and consulting fees incurred, valuation of options granted for consulting services during 2009, costs incurred for the shareholder meeting held in August 2009, and increased professional fees. The remaining general and administrative expenses include rent, office expenses and travel expenses. Our lack of cash has prevented us from paying all accrued salary and other expenses during the last eight years.
Principal amounts owed on notes payable totaled $285,206 and $280,491 at September 30, 2009 and December 31, 2008, respectively. Interest expense on these obligations during the three months ended September 30, 2009 and 2008 was $5,990 and $5,914, respectively.
Nine Months Ended September 30, 2009 and 2008
There were no sales during the nine months ended September 30, 2009 or 2008. For the nine months ended September 30, 2009, we had a net loss of $986,389, compared with a net loss for the nine months ended September 30, 2008 of $432,424. Our primary expense is payroll and other office costs, research, development, and consulting fees, together with interest expense and additional expense recorded as a result of options granted to consultants, and the extension of certain stock purchase warrants outstanding.
For the nine months ended September 30, 2008, we had no research and development expenses. For the nine months ended September 30, 2009, however, we incurred $305,883 in research and development costs, as a result of prototype development costs, consulting, and other research activities.
General and administrative expenses in the nine months ended September 30, 2009, were $617,377 compared to $342,889 during the same period in 2008. The increase in the current year as compared to the prior year was related
to additional payroll and consulting fees incurred, valuation of options granted for consulting services during 2009, costs incurred for the shareholder meeting held in August 2009, and increased professional fees. The remaining general and administrative expenses include rent, office expenses and travel expenses.
Principal amounts owed on notes payable totaled $285,206 and $280,491 at September 30, 2009 and December 31, 2008. Interest expense on these obligations during the nine months ended September 30, 2009 and 2008 was $17,818 and $24,444, respectively. Additional interest expense of $6,702 was recorded for the nine months ended September 30, 2008 on other outstanding indebtedness.
We also recorded debt forgiveness of $61,514 from a professional service firm during the nine months ended September 30, 2009.
Liquidity and Capital Resources
At September 30, 2009, our working capital deficiency was $3,265,784, compared to a working capital deficiency of $3,394,071 at December 31, 2008. The stockholders' deficit at September 30, 2009 was $3,479,870 compared to $3,615,326 at December 31, 2008.
As a development stage company, we have had no revenues. We will continue to require additional financing to fund operations and to continue to fund the research necessary to undertake our new business plans, to further the ongoing testing as previously described, and then to market a system for hospital and medical sterilization. Our only source of financing to date has been the periodic sale of common stock. During the nine months ended September 30, 2009, we generated cash of $768,000 through common stock sales at prices ranging from $0.02 to $0.03 per share. During October and November 2009, we raised an additional $232,100 through the sale of common stock at $0.06 per share.
However, we will need to raise additional capital in the near future in order to continue its research and development activities and to sustain operations.
We believe that we will be able to raise these additional needed funds from some of the same investors who have purchased shares during 2008 and 2009, although there is no assurance that these investors will purchase additional shares. However, these investors have verbally committed to continue to fund our projects on a monthly basis, as needed.
Our unaudited financial statements included in this report have been prepared on the assumption that the Company will continue as a going concern. Through the date of this report, it has been necessary to rely upon financing from the sale of our equity securities to sustain operations as indicated above. Additional financing will be required if we are to continue as a going concern. If additional financing is not obtained in the near future, we will be required to curtail or discontinue operations, or seek protection under the bankruptcy laws. Even if additional financing becomes available, there can be no assurance that it will be on terms favorable to the Company. In any event, this additional financing will likely result in immediate and possibly substantial dilution to existing shareholders.
Forward-Looking Statements and Risks Affecting the Company
The statements contained in this report on Form 10-Q that are not purely historical are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act. These statements regard our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of the words or phrases "believes," "expects," "anticipates," "should," "plans," "estimates," and "potential," among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-K for the year ended December 31, 2008 under the heading "Description of Business". The Company believes that many of the risks previously discussed and in its SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:
�
Rigorous government scrutiny and regulation of our products and planned products;
�
Potential effects of adverse publicity regarding ozone and related technologies or industries;
�
Failure to sustain or manage growth including the failure to continue to develop new products; and
�
The ability to obtain needed financing.
Critical Accounting Policies and Estimates
This Discussion and Analysis of Financial Condition and Results of Operations are based upon our unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of such statements requires management to make estimates and assumptions that affect the reported amounts of revenues and expenses during the reporting period and the reported amounts of assets and liabilities as of the date of the financial statements. These estimates are based on historical experience and other assumptions that management considers to be appropriate in the circumstances. However, actual future results may vary from these estimates, since by their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, we evaluate these estimates, including those related to bad debts, intangible assets, warranty obligations, product liability, revenue, and income taxes.
We account for equity securities issued for services rendered at the fair value of the securities on the date of issuance.
Recent Accounting Pronouncements
In June 2009, we adopted a new accounting standard for subsequent events, as codified in Accounting Standards Codification ("ASC") 855-10 (formerly SFAS No. 165, Subsequent Events), which establishes general accounting standards and disclosure for events that occur after the balance sheet date but before the financial statements are issued or are available to be issued. It requires the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date. This new standard is effective for interim and annual financial periods ending after June 15, 2009 and requires prospective application. The adoption of this new standard had no impact on our consolidated financial statements. We evaluated subsequent events through the date the accompanying financial statements were issued, which was November 9, 2009.
Effective July 1, 2009, we adopted the "FASB Accounting Standards Codification� and the Hierarchy of Generally Accepted Accounting Principles" (ASC 105), (formerly, SFAS No. 168, The FASB Accounting Standards Codification� and the Hierarchy of Generally Accepted Accounting Principles. This new standard establishes the "FASB Accounting Standards Codification�" (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (GAAP). Rules and interpretive releases of the Securities and Exchange Commission (SEC) are also sources of authoritative GAAP for SEC registrants. The Codification now supersedes all previous-existing Non-SEC accounting and reporting standards.
All other non-grandfathered Non-SEC accounting literature not included in the Codification has now become non-authoritative. Now that the Codification is in effect, all of its content carries the same level of authority. We believe that the adoption of this standard will not have a material impact on our consolidated financial statements.
well brian1980 I was on The Street in the 80's so let me give you just a little clue about "queue". There are some pretty big investors here & more have arrived over the last couple of days, with more coming & to protect our investment we are & have been sitting on bid support as the price rises we raise our level of support. This is where your lesson on queue comes in, "you're behind us already (& your order will be filled by the next available & they will be busy )because we have been in queue & if it does fall to your suggested level those shares will go to us". Sit back & watch or buy @ ask as we raise our support levels to follow rise in pps! This lesson was free, not acting will cost you.
Sky
From MEVT Board & it directly relates to my previous post as well
Posted by: Stock-Whisperer Date: Wednesday, November 11, 2009 5:04:06 PM
In reply to: JMoola who wrote msg# 2062 Post # of 2084 [Send a link via email]
now that post makes sense....thanks bro for saying it like it is.
this is going to take another run soon...we all watched in amazement as the stock ran up 300% in two days....its going to happen again....but this time it will keep on going...
im reading posts of people who are totally paniking....sheesh if you cant take the heat, stay out of the kitchen i say....i guess a one or two month investment is just too long for some of you.... im not big on the quick flips...lets face it, those quick flips are pump and dumps....this a real company and it takes time to conduct operation for a real company....the news is coming and so will the volume and price increase...if you think its taking too long to go up, sell your stock and get into some pump and dump and risk everything...
'
i say to those panik stricken people, stick to real estate investments, maybe this micro cap investing stuff just isnt for you...
vrooom vrooom, its coming....we are in a good place folks....you have to have faith
The Palace is expecting more great things today on MZEI & we have been told by Brent Oconnor of Geneva Bancourp that those little glitches (by shorts w/ some bordering being illegal btw) we have had with our other 2 picks MEVT & AWSL after their initial runs (of over 100+% each) are just about taken care of & taking off again, soon Hold your shares & add if you can. The only things these shorts have done is to make available to us discounted shares that we will never see this low again.
To Profits,
Sky
morning chrylaser...let's set that laser on some more profits
Popateer Sky
Popa was still analyzing the data from last night but is now enjoying some more Blue Mtn. Coffee that he has been drinking since 5:47. Damn wish I could sleep
Good morning Tex & howdy too
Sky
always looking out for new watches J & I'm not talking about telling time
Sky
Popateer is going to leave some analysis programs running & head to chambers with "whose your bad girl now" Popa & I will return later this evening to insert that data into another program. Will be here early as always ready for the fencing lessons as the Musketeers get ready to Protect the King &
in The Palace as on The Street Cash is our King.
Was a helluva day Palaceteers & tomorrow I expect will be better
See you all in the am as I am sure you all sleep more than this old Musketeer
Sky
AWSL readies itself to say good bye to the Skull & Bones
Sky
==========================
TORONTO -- (MARKET WIRE) -- 11/11/09 -- Atlantic Wind and Solar Inc. (AWSL:$3.1300,$0.0300,0.97%) is pleased to report that, in keeping with its clear focus on extraordinary opportunities in the dynamic Ontario Solar Power market, it has selected Toronto, Ontario as the location for its headquarters. Canada's largest city, Toronto is the epicenter of Ontario's Renewable Energy revolution. Located on Bay Street in the heart of Toronto's financial district, AWSL's new offices are being renovated for scheduled occupation in the first week of December 2009.
Our New Address
Atlantic Wind and Solar Inc. (AWSL:$3.1300,$0.0300,0.97%) 350 Bay Street, Suite 1201
Toronto, Ontario
Canada, M5H 2S6
Phone: 1 (800) 891-1657
Fax: +1 (888) 316-0424
Ontario Welcomes Renewable Energy
Atlantic's move to Toronto was prompted by the Ontario Government's global pace-setting Green Energy Act and lucrative Feed-in-Tariff (The "FIT" program), which provided a strong boost for AWSL's rooftop solar initiative. The incentives contained in the Province's progressive Green Energy Act are unequalled in North America and have been hailed as world leading in terms of encouraging the development of Renewable Energy projects. AWSL's Toronto headquarters will also house the Company's wholly-owned Canadian subsidiary, Atlantic Solar Inc., formed to focus on rooftop and ground mounted solar projects throughout Ontario.
Focused Squarely On Ontario Solar
Atlantic Wind and Solar (AWSL:$3.1300,$0.0300,0.97%) is now concentrating its marketing efforts on the exciting opportunities in the business of supplying, installing and, where appropriate, owning its leading edge Micro Energy Park rooftop and ground mounted solar PV systems in Ontario. This corporate focus emerged when the Government instituted its paradigm-changing Green Energy Act with its lucrative FIT program in September.
Recently, Atlantic Wind and Solar (AWSL:$3.1300,$0.0300,0.97%) received several Letters of Interest and/or Intent regarding deployment of its rooftop solar energy parks in Ontario as the interest in rooftop solar systems rapidly moved to a new level since September. Discussions are currently underway with various parties regarding additional AWSL Micro Energy Park rooftop solar projects.
Other News
Atlantic will not be proceeding with a study for the Morton Salt Company of Chicago to assess the feasibility of producing electricity from hybrid renewable energy ("RE") at its major salt producing facility on the island of Grand Inagua in the Bahamas. Morton Head office has put this project on hold until further notice, and AWSL management will not be pursuing this remote project in light of its new focus on Solar Energy in Ontario. Until further notice, potential Wind Power and hybrid Renewable Energy projects conflict with the Company's primary focus on Solar opportunities in Ontario.
AWSL and SEC-approved auditors Sam Kan & Company continue to work together towards achieving a listing status upgrade whereby the Company can ultimately elevate its share listing to a larger, higher profile venue for its share trading.
Sales and Marketing Contacts
To make Renewable Energy sales enquiries, please call +1 800 891 1657 ext. 230. Property owners and managers with unobstructed commercial rooftops of 30,000 s/f or bigger in the province of Ontario, Canada, and which they are interested in possibly leasing to AWSL, are invited to call Mr. Geoff Moffat, Cushman & Wakefield Ltd. at 416-359-2534.
SKYBOX TRADABLE LESSONS
1. Buy and Sell at the Ask
2. Patience = Profits
3. Volume Speaks Volumes & Volume Proceeds Price Action
4. Bid Sitters, You Can Not Practice Profits by Practicing to be Cheap!
5. When Dealing with Pinks do not Set Stop-Losses, Period
6. Shorters can't Short if We/You don't Sell
These 6 simple lessons "will" increase the value of your portfolio & you can take that to the bank!
FOR PALACE ALERTS send your email address, name & IHub alias to
profit_palace@yahoo.com
Add profit_palace@yahoo.com to your contacts list as not to be blocked out by your Spam Filter. You do not want to miss these email alerts!
Thanks
Sky
you always do Lou, you keep me in perspective
Thanks,
Sky
Thanks CT...do love that new word Wowzer MZEI
Sky
there were no large spikes in the pps of MZEI today as the pps increase was do to sheer volume. With very strong bid support & believe me there is some STRONG BID SUPPORT there is no room for flippers @ this time & with nice controlled buying & subsequent raising of the bid support we will see a healthy consolidation only when the volume dictates. @ this point we are setting ourselves up for the perfect storm.......
1) higher highs with higher lows when we consolidate = a healthy stock
2) and resistance levels now becoming support levels
3) more news on the way = the Perfect Storm
Sky
thanks for all your help j
Sky
Mr. 101 had an order in for 101 @ .401 & they held it off until after close & printed a (t) trade so as not to let us paint the close. Have even more faith as this just shows you where this is headed & how hard they are trying to keep it down. this one will be reported to the Market Table as @, 401 it is required to be filled 2 ask & in a timely fashion by SEC Rules & it was not!
Sky
Volume always precedes price
& look @ our volume, & wait as more yet to come
Sky
I would say you can bank on it Lou, I am!
Sky
There is more DD on this board than most will ever find for any play & it's all available @ the click of your mouse. DD, do some then make some $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Sky
giddy up MEVT you've been walking long enough & I feel something in the air, the call of the wild...and before she runs again, everybody hold tight to the reins. We all know how she gallops when she knows a storm is approaching, lest we forget
Sky
When there is no disease prevalent no need to treat! Medizone Intl. working towards total eradication & the health & safety of all. The $$$$$$ value of that is
Priceless
Sky
Everybody Profits More When they Buy & Sell @ Ask
not MHO just fact!
Sky
I slap a little every day & when this $i$ch runs it will be my payday
or @ least payback!
Just to interject a little humor, or try
Sky
An oldie but goodie! Wanted to pull this back up & ask how long do you think it will be before the next uplisting
No looking back from NASDAQ because the Sky's the Limit with MZEI
Sky
Posted by: Threw-er-back Date: Monday, October 19, 2009 6:09:23 AM
In reply to: None Post # of 2233 [Send a link via email]
Uplisting is always a beautiful thing ;o)
Medizone International, Inc. Announces OTCBB Listing
SAN FRANCISCO, Sept. 8 /PRNewswire-FirstCall/ -- Developer of ground-breaking ozone-based hospital sterilization technology -- AscepticSure(TM), Medizone announced today that its common stock has begun trading on the OTC Bulletin Board (OTC Bulletin Board: MZEI - News). The company's common stock was previously quoted on the Pink Sheets.
"While we have noticed over the past several months that many companies are de-listing from NASDAQ and the OTCBB due to various conditions and circumstances, we are pleased that we have moved up on the listing ladder to the OTCBB from the Pink Sheets," said Edwin G. Marshall, Chief Executive Officer of Medizone. "We are pleased to take this step to increase the company's exposure to investors and market makers, enhance liquidity for shareholders and institutions, and bring an added credibility to our common stock," continued Mr. Marshall.
Medizone International, Inc., is a research and development company engaged in developing its' AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Trials conducted at Medizone's laboratory located in Innovation Park at Queens University have proven very successful and will now proceed to a hospital mock-up followed by hospital beta testing of the production prototype.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Like to protect my investment with a little help from my friends!
Sky
AWSL
Posted by: Doubloon Date: Wednesday, November 11, 2009 9:09:37 AM
In reply to: Doubloon who wrote msg# 3840 Post # of 3851 [Send a link via email]
MATERIAL CONTRACTS
A. MATERIAL CONTRACTS ENTERED INTO IN PAST TWO YEARS
The company entered into an agreement with the Hyberdyne Group of Companies to buy, market
and sell a inverter / Converter technology which currents research points to an significant power
output improvement when used with wind turbines and solar PV arrays.
The Company entered into a Investment Banking and Investor Relations agreement with Geneva
Bancorp Inc. covering a 12 month term for 500,000 restricted common shares.
1. Cushman & Wakefield Ltd.
Atlantic Wind and Solar has formed a Strategic Alliance with Real Estate and Property
Management leader Cushman & Wakefield Ltd. to secure rooftop leases throughout Ontario for
AWSL's photovoltaic (PV) renewable energy systems. The program involves securing long-term
lease agreements for commercial rooftops, in exchange for attractive lease payments to the
building owners. Real Estate brokerage and Property Management leader Cushman & Wakefield
has broad industry relationships with the major landlord and building owners across Ontario.
Cushman & Wakefield Ltd. is a unit of the world’s largest privately owned real estate services
firm, Cushman & Wakefield Inc., founded in 1917 in New York City. With approximately 200
offices in nearly 60 countries on six continents, the Company is a global leader in promoting
energy efficient buildings and sustainable real estate development, and has won many awards
internationally for its leading edge practices over the years. Across Canada, Cushman &
Wakefield has a leading reputation among brokerage firms and possess strong proficiency with
C-Level sales, contract and lease negotiations. Regarding sustainability, Cushman & Wakefield
believes that “Active support for sustainability leads to better, more profitable buildings, with
higher occupancy rates from better covenant clients. Ignoring it will become increasingly
unprofitable.”
2. Aird & Berlis LLP
Atlantic Wind and Solar has retained the Toronto, Ontario-based law firm of Aird & Berlis LLP
to assist in its business of renting rooftop space to facilitate rooftop solar energy parks
throughout Ontario.
Aird & Berlis comprises a diverse group of more than 120 lawyers. The firm provides a wide
range of legal services that includes a dedicated Energy Team with strong capabilities in various
facets of the Renewable Energy sector, as well as its industry leading Real Estate Group serving
major developers of commercial, institutional, residential and industrial real estate.
The retention of Aird & Berlis LLP is in keeping with Atlantic Wind and Solar's policy of
aligning the Company with leaders in relevant businesses and services.
3. Sam Kan & Company
Atlantic Wind and Solar has retained SEC auditor Sam Kan & Company to audit the last 2 fiscal
years with the intention of filing with the SEC to become a reporting Issuer seek a move AWSL
forward towards achieving a listing status upgrade whereby the Company can elevate its share
listing to a larger, higher profile stock exchange.
B. CONTRACTS WITH MANAGEMENT OR OTHERS
With the exception of Charles Mazzacati, VP of Atlantic Solar Inc. The company has no
employment contracts with anyone.
Issuer’s president, CTO, CFO and directors works at the pleasure of Issuer’s Board of Directors
and is compensated 65,000 shares a year each.
AWSL
Posted by: Doubloon Date: Wednesday, November 11, 2009 9:07:53 AM
In reply to: Doubloon who wrote msg# 3838 Post # of 3851 [Send a link via email]
The payment for employee services issue is answered
Fiscal Year 2009 1st Quarterer
During the first quarter 2009 the Company had no revenue and posted a net loss of
$9,002.31. During this period management continued to work without pay for future
considerations. Management will continue to work without pay until such time as sales can
support salaries. During the quarter the Company entered into negotiations to acquire a
income producing renewable energy company which it hopes to complete this fiscal year.
However there can be no assurance that management will be successful in its bid to acquire
this business.
AWSL
Posted by: Doubloon Date: Wednesday, November 11, 2009 9:01:17 AM
In reply to: Doubloon who wrote msg# 3837 Post # of 3851 [Send a link via email]
THE NATURE AND EXTENT OF THE ISSUER’S FACILITIES.
1,200 square feet of office space in Toronto for the Company’s sales office for its
Rooftop Solar Division (Atlantic Solar Inc.) at a cost of approx. $4,000. per
month. The space host a board room and enough space for the sales and
administration of the company.
AWSL
Posted by: Doubloon Date: Wednesday, November 11, 2009 8:58:20 AM
In reply to: Doubloon who wrote msg# 3836 Post # of 3851 [Send a link via email]
Business plan outline
The first goal of Atlantic Wind and Solar was/is to attain a position at the forefront of
emerging technologies and to leverage that position into renewable energy solutions for all.
Besides the obvious focus on wind and solar energy AWSL also concentrates on the power
conversion/inversion aspect of these technologies to increase efficiency for renewable
projects both new and existing.
With the recent announcement of a renewable energy mandate by the Canadian Province of
Ontario, Atlantic Wind and Solar immediately shifted its focus to rooftop solar projects in that
province. The new Ontario FIT represents an immediate opportunity that is currently
unparalleled in North America and possibly the world. Through the Ontario Power Authority’s
(OPA) Feed-In Tariff Program the government is guaranteeing the purchase of power from
renewable sources for the next 20 years. In a bid to phase out coal-fired electricity generation by
2014, and to avoid building a new nuclear power plant, the Government of Ontario has
committed to financially encouraging over 3,000 MW of new energy capacity from renewable
sources. In the words of the government itself: “Ontario's feed-in tariff or FIT Program is North
America's first comprehensive guaranteed pricing structure for renewable electricity production.”
Atlantic Wind and Solar’s current business plan for the next 5 years is based on achieving a share
of the Ontario Rooftop Solar PV market as driven by the OPA’s FIT program. AWSL’s advantage
is in its strategic partnership with Hybridyne Power Systems Canada. Management feel the
Hybridyne power system on average generates more electricity, and thus revenue , than similar
renewable energy systems.
While participating in this boom in solar technology Atlantic Wind and Solar continues, through
strategic partnerships, to position itself to for future projects using the ultimate source of low cost
energy, wind.
From AWSL Board
Posted by: Doubloon Date: Wednesday, November 11, 2009 8:53:56 AM
In reply to: None Post # of 3851 [Send a link via email]
For the skeptics that do not understand business addresses
ADDRESS OF ITS PRINCIPAL EXECUTIVE OFFICES;
Head office:
350 Bay St. Suite 1201, Toronto ON M5H 2S6
Tel: +1 800 891-1657
Fax: +1 888 316-0424
USA Mailing Address:
3109 Grand Avenue, Suite 484, Coconut Grove FL 33133
East Coast Canada:
974 Topsail Road, P.O. Box 221 Mt. Pearl, Newfoundland A1N 2Y2
Bahamas office:
29 Retirement Road, Off Albury Lane, Shirley Street, Nassau.
somebody has to hold the, shall we say Single Malt Petro
Sky
slow & steady increases in the pps will keep out the flippers as we will have their eyes soon enough but with the proper control of the bid support not their actions
Remember a Company shows it's health when we reach higher highs & yet consolidate with higher lows. Resistance then becomes support & we march onward & upward!
Sky
for now I've just got out my BYSD Petro surfboard as I am always on look out for the perfect storm
Sky
Thanks oh Lord of the IBox
Sky
glad to hear you are taking care of yourself buddy.
Popateer Sky
Two words...
small float
then all it takes is more patience,
Sky
I do believe once hospitals see how much they can save for every dollar spent on this technology it will be a billion $ industry.
Sky
A long read but well worth $$$$$your time.
Thanks Pisa,
Sky
MZEI ON HIGH ALERT, DD HERE:
is a research and development company engaged in developing its
AsepticSure(TM) technology to decontaminate and sterilize hospital
surgical suites, emergency rooms, intensive care units, schools and
other critical infrastructure.
Perhaps some of you caught this post when it was @ .14
Post Date: 11/6/2009 9:27:31 AM
Board: Chrissy's Profit Palace
biotechs to watch:
AVXT, MZEI
If you did "watch" you surely then saw this post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43409389
The stock has since made an extremely bullish move from .14 to .19 as
of this writing @ 10:40am and I simply can't keep this to myself any
longer as I think we are on the cusp of something truly special...
link to the MZEI board:
http://investorshub.advfn.com/boards/board.aspx?board_id=103
5 week volume average comparison... for the period from 8/31-10/2
MZEI traded an average of 966,920 shares per week in which the the
share price ranged from .08-.10 (obviously a very tight range), the
period that followed, from 10/5-11/6 saw a 139% increase in average
weekly volume to 2,316,680 shares per week in which the the share
price ranged from .07-.16 (with a close on 11/6 @ .16)
Medizone Consultants
Dr. Ronald K. St. John--As a board-certified physician in preventive
medicine, with post-graduate training in internal medicine, infectious
diseases, and public health, Dr. St. John has 35 years of experience
in the management of medical science for public health programs,
legislation, and policy development. During his career, he has
developed and managed large and small scale infectious disease control
programs in domestic and international environments. Shortly before
the 9/11 attacks in the US, he was appointed as a Director-General in
the Canadian Department of Health with responsibility for developing
Canada’s first Centre for Emergency Preparedness and Response for
crises and disasters affecting the health of the public. He retired
from this position in February 2007.
Dr. St. John began his public health career as a commissioned officer
in the US Public Health Service, assigned to the US Centers for
Diseased Control and Prevention. Through his work in domestic and
international organizations, he acquired an extensive understanding of
US Public Health Service institutions, the US and Canadian governments
and their states, provinces and territories, the Pan American Health
Organization (The World Health Organization's Regional Office for the
Americas), the World Health Organization and domestic and
international non-governmental and development organizations.
During his tenure with the Canadian Department of Health and
subsequently the Public Health Agency of Canada, he rebuilt the
Canadian Quarantine Service, co-founded the Global Public Health
Intelligence Network (GPHIN - a 24/7 global electronic monitoring
system of all infectious disease outbreaks worldwide), modernized the
Canadian National Emergency Stockpile System (a national network of
strategically placed depots containing emergency medical supplies
worth over $300 M) and established the first federal focus for medical
counter-terrorism.
Dr. St. John graduated from three distinguished Ivy League
Universities (BA from Yale University, MD degree from Columbia
University and Masters in Public Health from Harvard University).
Dr. Dick Eric Zoutman
Professor and Chair,
Divisions of Medical Microbiology and of Infectious Diseases, Queen's University
Medical Director of Infection Prevention and Control Services,
University Hospitals Kingston, Kingston, Ontario--Dr. Dick Zoutman has
been practicing medicine for over 20 years and specializes in Internal
Medicine, Infectious Diseases and Medical Microbiology at Queen's
University at Kingston. A primary focus of his investigative work has
been understanding the prevention and control of healthcare-associated
infections and related medical errors. Using a systems analysis
approach to examine healthcare operations, Dr. Zoutman has evaluated
antibiotic prescribing and utilization in the community, acute care
and long term care sectors. He has shed light on the factors that lead
to the over-prescribing of antibiotics in family practice, as well as
the failure of hospitals to successfully prevent surgical wound
infections by properly prescribing antibiotics to patients undergoing
major surgery. Dr. Zoutman continues to examine the impact of hospital
resource allocation and infectious adverse events, as well as the use
of information systems to improve the quality of patient care and to
reduce hospital acquired infections. Dr. Zoutman's work and
collaborations have spanned the globe from North America, South
America, the Balkans, the Middle East and Africa.
He is Physician-Director of the Board of the Community and Hospital
Infection Control Association of Canada. During the 2003 outbreak of
SARS in Toronto Dr. Zoutman chaired the Ontario SARS Scientific
Advisory Committee responsible for advising the Ontario government on
outbreak management strategies.
Dr. Zoutman is Chair of the National Bioterrorism Contingency Task
Force for Hospitals; and a member of the Infection Control Guidelines
Steering Committee and the Canadian Nosocomial Infection Surveillance
Program. Dr. Zoutman is also Chief of the Department of Medical
Microbiology and Medical Director of Infection Prevention and Control
at the South Eastern Ontario Health Sciences Center in Kingston. Dr.
Zoutman is professor of Pathology & Molecular Medicine, of Community
Health and Epidemiology, and of Medicine in the Faculty of Health
Sciences at Queen's University.
Development Team:
Dr. Michael E. Shannon
Dr. Dick Eric Zoutman
Gunter Moldzio-- C.E.O. of Biozone
Bernard Lim-- JTL Global Ventures (he usually commands $3,000 a day
for his consulting services but Medizone has negotiated to compensate
him $1,000 a day and he has exercisable options for when the company
reaches various stages of it's business model, for instance 500,000
shares exercisable when beta testing starts... why is so sure it's
going to start? Seems pretty confident in Medizone)
Dr. David Barnes
Robert Hirons-- Cohspat Corp.
Brad Goble-- TDV Global
Brady Allin-- TDV Global
(I implore you to google/research/whatever you do to do DD all of the
above names and tell me if you can find a red flag because I can't,
and trust me, I tried...)
As for the leader of the clan? A fearless one:
Edwin G. Marshall - Chairman of the Board and Chief Executive Officer
Mr. Marshall has served as Chairman of the Board since June, 1997 and
Chief Executive Officer since March, 1998.
Mr. Marshall attended Santa Rosa Community College and the College of
Marin, studying fire science and business administration. Until 1978
Mr. Marshall worked in the fire service in a city with a major
chemical industrial complex, leaving with the rank of Captain. He was
a successful private investor in precious metals, securities and real
estate and workeed in the real estate brokerage business pursuing
from 1978 until 1995 various business interests including the real
estate brokerage, a vacuum forming business in the plastics industry,
an industrial computer controls company, and an automobile and truck
dealership.
Since 1997 he has devoted all of his business time to management
responsibilities with Medizone.
(furthermore, what the website does not mention is how Marhsall came
to be c.e.o.... After being a large shareholder of MZEI in the 90's he
began to get fed up with management at the time as he felt that the
c.e.o. had been pocketing money from shareholders instead of putting
it to use with the company. What did he do? Went to the state's
attorney and asked if he could prosecute him, the state's attorney
told him he couldn't because the case was to small. Well, being the
ambitious work horse Ed is, he built the case HIMSELF, and as I
understand brought 2 very thick manilla folders back to the state's
attorney and asked him once more if he could prosecute the guy. The
state's attorney, impressed with the fact Ed took did all the work on
his own took up the case and the sucker did 5 years time and repaid
shareholders upwards of $400,000. That's the type of guy Ed is. Then
in the the middle of the 2000's he was approached by a couple
shareholders who said they would fund $2,000,000 privately to the
company if Ed would just do a reverse split and try and help get
things moving. Ed made a point to say that the company was closer to
going under than it was proceeding with operations at the time of this
proposal. read below)
___________________________________________________________________________________________________
THE SAND DOLLAR SOLUTION
144 BUENA VISTA
P.O. BOX 742
STINSON BEACH, CALIFORNIA 94970
May 6, 1997
My Fellow Medizone International, Inc. Shareholder's,
I believe a moment of truth and opportunity is before you. Our Company
is in a desperate situation. Current management, led by Joseph Latino for the
previous three years, has failed to fund or manage Medizone in a viable manner.
At this time, Medizone is financially insolvent. Research is not progressing and
three Board members: Larry Sosnow, Richard Solomon, and Howard Feinsand have all
resigned in the previous seven months. A fourth, Ken Gropper, has threatened
resignation if the resignation or firing of Joseph Latino is not achieved.
In our view Medizone is not only dysfunctional, for all practical
purposes it is a non-entity. When Joseph Latino became President of Medizone the
stock was trading at approximately $0.32 per share. Today it is trading just
above $0.05.
The enclosed proxy, which I strongly ask you to support, offers the
opportunity to elect four very qualified members to the Board, as well as to
approve a financing package that is above current market prices. These changes
will allow us to install new and professional management, begin a positive
corporate direction and once again advance the science.
Milton Adair will lead the new management team and will personally
select a new CEO from the applicants we are currently reviewing. Milton brings a
35 year business background in the bio-tech industry. His leadership strengths
vary from sales and marketing to product development and FDA relations.
Gerard Sunnen, M.D. has been involved with Medizone for over 10 years.
He first studied the use of ozone in Germany in 1986. A published ozone
researcher, Dr. Sunnen has strong professional ties in Europe. He will be an
excellent liaison for Medizone with the Italian researchers, without needing an
interpreter.
William Hitt, M.D. brings a renowned background. A long time member of
The World Health Organization, and recipient of the prestigious Eli Lily award
for his discovery and report of new anaerobic species of mycoplasma, Dr. Hitt
has not only instructed immunology at both John Hopkins University and Louisiana
State University he brings research and business expertise to the Board as well.
The strongest remark I can make about my own qualifications is that I
have been able to formulate this plan, form Sand Dollar Solution, a financial
arm of this endeavor, and bring these
distinguished people together. There is no doubt in my mind we will succeed. We
do ask your timely support in order to accomplish this.
Richard Solomon, a former Board Member and Director of Medizone New
Zealand was asked to join this effort. While he declined to be a candidate for a
Board seat at this time, he did pledge his full support to these efforts, and
gave us permission to use his name. With his background and knowledge as a Board
Member up until February 27 of this year, Richard is well aware of the
challenges we face, and will be of vital help to the new management team.
As you review the proxy, particularly the section entitled, "Sand
Dollar's Complaints Concerning Management", I believe you will see what grave
circumstances the company is in. My personal evaluation is that the Company is
currently not in a survivable situation. Please help us change that.
I strongly urge you to carefully read the proxy and carefully fill out
the proxy card to insure we will be able to count your vote. Your company is at
stake. Please follow through with this proxy request immediately.
I thank you very much for your support, without which, these efforts
would be futile.
YOURS TRULY,
EDWIN G. MARSHALL,
BOARD NOMINEE
FOUNDER, MEDIZONE SHAREHOLDER'S GROUP
MANAGING AND GENERAL PARTNER,
THE SAND DOLLAR SOLUTION,
A CALIFORNIA LIMITED PARTNERSHIP
___________________________________________________________________________________________________
some recent s.e.c. filings to take note of:
Form S-8 - Securities to be offered to employees in employee benefit plans:
http://sec.gov/Archives/edgar/data/753772/000117935009000069/0001179350-09-000069-index.htm
Form 10-Q - Quarterly report:
http://sec.gov/Archives/edgar/data/753772/000117935009000054/0001179350-09-000054-index.htm
Please do look over those, and look over the many reports they have
filed (which include PR's as well):
http://sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000753772&type=&dateb=&owner=exclude&start=0&count=40
useful links:
management team w/profiles--
http://medizoneint.org/medizone-international-inc-otc-mzei/management/
research:
http://medizoneint.org/asepticsure™/research/
corporate strategy:
http://medizoneint.org/medizone-international-inc-otc-mzei/our-strategy/
2009 press releases:
http://medizoneint.org/investor-relations/shareholder-communications/november-10-2009-mrsa-breakthrough-announced-for-asepticsure™-hospital-sterilization-system/
http://medizoneint.org/investor-relations/shareholder-communications/sept-8-2009-medizone-international-inc-announces-otcbb-listing/
http://medizoneint.org/investor-relations/shareholder-communications/august-5-2009-medizone-expects-otcbb-listing/
http://medizoneint.org/investor-relations/shareholder-communications/july-13-2009-medizone-international-inc-has-filed-for-patent-protection-for-asepticsure-hospital-sterilization-system/
http://medizoneint.org/investor-relations/shareholder-communications/july-7-2009-medizone-international-inc-announces-it-has-established-its-own-bsl2a-certified-laboratory-located-in-innovation-park-queens-university-at-kingston-ontario-canada/
2008 press releases:
http://medizoneint.org/investor-relations/shareholder-communications-2008/san-franciscocalifornia-november-4-2008-medizone-international-inc-mzei-pk-announces-consulting-relationship-with-tdv-global-inc/
http://medizoneint.org/investor-relations/shareholder-communications-2008/oct-30-2008-medizone-international-inc-establishment-of-canadian-foundation-for-global-health/
http://medizoneint.org/investor-relations/shareholder-communications-2008/oct-1-2008-medizone-international-inc-mzei-pk-announces-hospital-sterilization-initiative/
http://medizoneint.org/investor-relations/shareholder-communications-2008/september-26-2008-medizone-international-appoints-equiti-trends-advisors-as-shareholder-relations-firm/
http://medizoneint.org/investor-relations/shareholder-communications-2008/medizone-international-inc-appoint-dr-michael-shannot-to-board-of-directors/
(These guys do not put out fluff PR's, but you already know that
because you just read every press release)
2009 annual shareholder meeting:
http://medizoneint.org/news-and-events/579/
POWERPOINT MUST SEE!!!
http://sec.gov/Archives/edgar/data/753772/000109690609001058/mzei8k20090826ex99.htm
_______________________________________________________________________________________
Guys and Gals, I cannot pound the table harder and say that NOW IS THE
TIME TO BE APART OF SOMETHING TRULY SPECIAL! Medizone has a product
the market needs, I can tell you personally, having several family
members in the medical field, they are ALL impressed and optimistic
with what Medizone hopes to achieve. I spoke with Mr. Marhsall
extensively on Monday (11/9) and he told me that he felt shareholders
would have reason to be VERY excited very soon, little did I know that
meant a press release was coming out today. For all who haven't seen
it, you must:
http://ih.advfn.com/p.php?pid=nmona&article=40291110&symbol=MZEI
"Current trials are now being expanded to include a hospital mock-up
to be followed by hospital beta testing. Initial sales are targeted to
commence early in 2010."
There's at least 3 juicy PR's right there... not to mention Ed told me
they would by filing Q3'09 by the "end of the week."
Do your own DD as always, I think when you do you will realize this is
not your average pick. As always take profits when appropriate but I'm
telling you now, if everything falls into place this stock will change
lives, both financially and physically. If you think I'm joking, just
watch what happens over the coming months/years...
Pisa & Sky
(please note: this is the first INTIAL DD report that is to going to be followed up with MULTIPLE posts digging deeper and deeper into MZEI)
here's some posts I think people should take the time to read:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43435866
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43435770
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43428747
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43427746
NOT TO GO UNNOTICED:
These guys file with the S.E.C. regularly and I am told we have another one coming;
http://sec.gov/cgi-bin/browse-edgar?company=medizone+international&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany